Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13187MR)

This product GTTS-WQ13187MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hyperlipidemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13187MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14396MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ13415MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ14772MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ9355MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ15175MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ15468MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ10797MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ13753MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN 1500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW